Conference
34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP)
Authors
McKenzie M; Chi K; Neville A; Ellard S; Baerg B; Ruether D; Winquist E; Segal R; Attwell A; Lukka H
Volume
80
Pagination
pp. s10-s11
Publisher
Elsevier
Publication Date
September 2006
DOI
10.1016/s0167-8140(06)80775-9
Conference proceedings
Radiotherapy and Oncology
ISSN
0167-8140